@article{discovery10076682,
           title = {Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease.},
            year = {2019},
         journal = {Clinical and Translational Science},
          number = {3},
           month = {May},
           pages = {240--246},
          volume = {12},
            note = {This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
https://creativecommons.org/licenses/by/4.0/},
             url = {https://doi.org/10.1111/cts.12619},
            issn = {1752-8062},
        abstract = {The Critical Path for Parkinson's (CPP) Imaging Biomarker and Modeling and Simulation working groups aimed to achieve qualification opinion by the European Medicines Agency (EMA) Committee for Medical Products for Human Use (CHMP) for the use of baseline dopamine transporter neuroimaging for patient selection in early Parkinson's disease clinical trials. This paper describes the regulatory science strategy to achieve this goal. CPP is an international consortium of three Parkinson's charities and nine pharmaceutical partners, coordinated by the Critical Path Institute.},
          author = {Romero, K and Conrado, D and Burton, J and Nicholas, T and Sinha, V and Macha, S and Ahamadi, M and Cedarbaum, J and Seibyl, J and Marek, K and Basseches, P and Hill, D and Somer, E and Gallagher, J and Dexter, DT and Roach, A and Stephenson, D and Critical Path for Parkinson's (CPP) Consortium, {} and Parkinson's Progression Markers Initiative (PPMI), {}}
}